NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: SCHOTT North America
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Ypsomed Collaborates with SCHOTT and Lonza to Develop A Comprehensive Solution for Combination Products Based on Patch Injectors - Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT and Lonza for the development, manufacturing and testing of pharmaceuticals - Ypsomed.ch / Lonza.com / SCHOTT.com
Ypsomed Collaborates with SCHOTT and Lonza to Develop A Comprehensive Solution for Combination Products Based on Patch Injectors

 

NewswireToday - /newswire/ - Burgdorf, Switzerland, 2020/11/09 - Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT and Lonza for the development, manufacturing and testing of pharmaceuticals - Ypsomed.ch / Lonza.com / SCHOTT.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Ypsomed advances its patch injector into a comprehensive solution by entering into a collaboration with SCHOTT, one of the leading suppliers of pharmaceutical primary packaging, and Lonza, a leading global partner of the pharmaceutical and biotechnology industry for the development, manufacturing and testing of pharmaceuticals. In a joint effort, the three companies are developing a comprehensive solution for wearable patch injectors for the subcutaneous self-injection of large volumes of liquid formulations. This solution should enable pharmaceutical companies to quickly bring biopharmaceuticals in a patch injector into the clinical trial stage and to the market. For patients, the solution reduces the number of hospital visits required for treatment.

Ypsomed has entered into a collaboration with SCHOTT and Lonza to be able to offer the YpsoDose patch injector platform, which is used for the subcutaneous self-administration of high volumes of pharmaceuticals, as a fully integrated solution. The three partners are cooperating closely to develop all the necessary components and manufacturing processes. This will enable customers to enter into clinical trials quicker with their drugs - often sensitive biopharmaceuticals - and commercialise them in less time. The comprehensive solution includes a ready-to-use cartriQ® glass cartridge from SCHOTT as the primary packaging for the drug, the YpsoDose patch injector platform from Ypsomed, and the processes for filling, assembly and testing of the final product by Lonza Drug Product Services (DPS). Pharmaceutical customers will thus receive a tested and documented overall solution and can concentrate on their core business.

Flexibility and know-how
This collaboration brings together three experts in their respective fields. All the processes and components of the solution are pre-developed, coordinated and tested. This is a crucial aspect as there are currently no established primary packaging materials for patch injectors and therefore no corresponding filling solutions. SCHOTT develops and supplies 10ml ready-to-use cartriQ® cartridges for the YpsoDose. These cartridges require fewer process steps during filling than conventional cartridges. Lonza Drug Product Services applies its expertise in process development, testing and characterisation and implements a filling and assembly process for YpsoDose in Stein (Switzerland) to provide short implementation times for customers.

Andreas Reisse, Head of SCHOTT Pharmaceutical Systems, explains: "With this new development, for which we have also made investments at our Swiss site, we are making it possible for us to jointly optimise processes for pharmaceutical companies. At the same time, we are creating completely new possibilities in the area of self-medication in terms of drug safety and user-friendliness. This is fully in line with our aim of always acting in the best possible way for the benefit of human health."

Prof. Dr. Hanns-Christian Mahler, Head of Lonza Drug Product Services adds "The know-how and expertise of Lonza DPS in the development, manufacturing and testing of formulations and sterile products for subcutaneous administration is the ideal basis to enable our pharmaceutical and biotech customers to develop and commercialise the YpsoDose patch injector."

Ypsomed's platform gives customers considerable freedom in the choice of components and partners to implement their own processes as necessary. The advantage of the comprehensive solution, however, is that the three partners combine their know-how and together provide all the necessary processes and components for a short time-to-market of biopharmaceuticals. "Together with strong partners, we offer a comprehensive solution for patch injectors so that our customers can bring their active substances and drugs to market as a commercialisable product in a short time and at low cost," says Ulrike Bauer, Senior Vice President Delivery Systems at Ypsomed.

About Ypsomed Group

Ypsomed (ypsomed.ch) is the leading developer and manufacturer of injection and infusion systems for self-medication and a well-established diabetes specialist with 30 years of experience. As an innovation and technology leader, it is the preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid drugs. Ypsomed presents and markets its product portfolios under the umbrella brands mylife™ Diabetescare directly to patients or via pharmacies and clinics and under YDS Ypsomed Delivery Systems in the business-to-business sector to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and has a global network of production sites, subsidiaries and distribution partners, employing some 1,800 people worldwide.

Contact: Thomas Kutt - Head Investor Relations
T: +41 34 424 35 55 - E: thomas.kutt[.]ypsomed.com.

About SCHOTT

SCHOTT is a leading international technology group in the areas of specialty glass, glass-ceramics and related high-tech materials as well as in the field of parenteral packaging for the pharmaceutical industry. With over 130 years of experience, the company is an innovative partner to many industries, including the home appliance, pharma, electronics, optics, life sciences, automotive and aviation industries. SCHOTT has a global presence with production sites and sales offices in 34 countries. In the 2018/2019 fiscal year, the group generated sales of around $2.54 billion with over 16,200 employees.

Contact: Matt McLoughlin - Gregory FCA on behalf of SCHOTT
P: 610-228-2123 - E: matt[.]gregoryfca.com.

About Lonza
At Lonza (lonza.com), we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors. We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment. Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15 500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion.

Contacts:
Dr. Sanna Fowler - Head of External Communications
T: +41 61 316 8929 - E: sanna.fowler[.]lonza.com.

Dirk Oehlers - Investor Relations
T: +41 79 421 1609 - E: dirk.oehlers[.]lonza.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: SCHOTT North America

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Ypsomed Collaborates with SCHOTT and Lonza to Develop A Comprehensive Solution for Combination Products Based on Patch Injectors

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Rina Della Vecchia - SCHOTT North America, Inc. 
914-831-2286 rina.dellavecchia[.]us.schott.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SCHOTT North America securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From SCHOTT North America / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing
DSM Acquires Flavor & Fragrance Bio-based Intermediates Business from Amyris
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo®
DSM and Industry Partners Launch Coalition to Close the Loop on Dyneema® - The World’s Strongest Fiber™
Pharmactive Earns Acclaim from Frost & Sullivan for Helping People Improve their Cognitive Functions with its Saffron-based Ingredient, Affron®
Tergus Lauded by Frost & Sullivan for its Full-spectrum CRO Services for Therapeutics in Dermatology
Sunquest Lauded by Frost & Sullivan for Driving Efficiency and Compliance with its Differentiated Molecular Laboratory Information Management System
DSM Launches Three Times Faster-acting Form of Vitamin D Supplement in Australia to Support Immune Health
Ipsen Announces New Data from the Phase II CLARINET FORTE Study
South Carolina-based IMCS Awarded Major NIH Research Grant
Preventive Healthcare Measures to Combat Obesity and Lifestyle Diseases Steer Demand for Nutritional Lipids Globally Finds Frost & Sullivan
Covance, LabCorp’s Drug Development Business, Acclaimed by Frost & Sullivan for its Unmatched Breadth of Services to Support Clinical Trials
Clariant Lauded by Frost & Sullivan for Addressing the Growing Customer Demand for Natural Anti-aging Active Ingredients with its Product, Prenylium®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Limelon Advertising, Co.





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)